Drugs News and Research

RSS

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

Forest Pharmaceuticals to pay $300 million as penalty for criminal actions

The U.S. Food and Drug Administration (FDA), working in close coordination with the U.S. Department of Justice (USDOJ), today announced that Forest Pharmaceuticals, Inc. entered into a plea agreement in which the company accepted responsibility for criminal actions including distribution of an unapproved new drug, distribution of a misbranded drug, and obstruction of an FDA inspection.

16 Sep 2010

NMS Labs launches method for K2 drug metabolites detection in urine

Of growing concern to public health officials and law enforcement is that routine drug testing cannot detect the use of the popular and highly intoxicating new drugs K2 and Spice. NMS Labs now has a full menu of tests that can detect the use of the designer chemicals present in these products, sold as incense or legal highs. A few weeks ago, NMS Labs launched a blood test to detect a range of these laboratory-designed synthetic drugs.

16 Sep 2010

Generics drugs in Medicare program saved $33 billion in 2007: CBO

New research released today by the Congressional Budget Office (CBO) found that the use of generic medications rather than brand-name medications in Medicare Part D saved beneficiaries and the program about $33 billion in 2007, while an additional $14 billion in savings is expected as first-time generics enter the market through 2012.

16 Sep 2010

Anonymous Funding promotes drug development for Fragile X syndrome treatment

Funding from an anonymous wealthy family has been the secret to progress, at long last, in developing drugs that show promise for helping millions of people worldwide with Fragile X syndrome, the most common genetic cause of autism. That's the topic of a fascinating article in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

16 Sep 2010

Researchers to conduct gene analysis for ankylosing spondylitis

A new study designed to test suspected links between genes and two immune disorders could open the door to better ways to diagnose and treat the conditions that affect a combined total of approximately 2.5 million people in the United States, report scientists at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2010

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT and the weight loss medication sibutramine (sold as Meridia® in the United States).

16 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

Wistar Institute scientists publish detailed report on structure, function of Cdc13 domain in protein

Scientists at The Wistar Institute have published the first detailed report on the structure and function of a crucial domain in the protein known as Cdc13, which sustains telomeres by clamping to DNA and recruiting replicating enzymes to the area.

16 Sep 2010

Researchers target specific molecule in brain to prevent relapses in cocaine addicts

People who have used cocaine run a great risk of becoming addicted, even after long drug-free periods. Now researchers at Linköping University and their colleagues can point to a specific molecule in the brain as a possible target for treatment to prevent relapses.

16 Sep 2010

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today participated in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

16 Sep 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

A new clinical trial supports the benefits to people with osteoarthritis who used a unique extract of turmeric. Scientists in Italy have studied the pain-relief, increased flexibility, and other effects of a special, patented extract of the roots of turmeric, the flavorful spice that has been used for centuries as a traditional remedy. Turmeric formulations have shown a wide range of safety and significant scientific and clinical benefits in recent animal research and human clinical trials.

16 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

HHS awards grant to develop patient-centered outcomes research

U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health, Howard K. Koh, MD, MPH, today announced the award of more than $14 million to develop, implement, and test strategies to increase the adoption and dissemination of interventions based on patient-centered outcomes research among racial and ethnic minority populations.

16 Sep 2010

Renal research consortia receives two grants for translational research from DKF

The Dutch Kidney Foundation (DKF) awards two Consortium Grants of 1,5 million euro to renal research consortia to concentrate on translational research.

16 Sep 2010

ESMO honors three eminent cancer specialists for their contribution towards medical research

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy.

16 Sep 2010

Daily doses of ginger relieve muscle pain: Research

Daily doses of raw or heat-treated ginger are effective for relieving muscle pain following strenuous exercise, according to research reported in The Journal of Pain, published by the American Pain Society.

16 Sep 2010

Milwaukee sees fast rise in costs of benefits; N.J. Gov. outlines cuts to public workers' benefits; Hawaii teachers file suit over health changes

"The cost of health benefits appears to be rising at a much faster pace in the Milwaukee area than the national average. Employers reported that the cost of health benefits increased 11% to 13% on average in the Milwaukee area this year, according to the 2010 Greater Milwaukee Employer Health Care Benefits Survey

16 Sep 2010

Report: Prevention efforts averted almost 750,000 child Malaria deaths over 10 years

Malaria prevention efforts - such as the use of bed nets, indoor insecticide spraying and the use of drugs to prevent the disease - have prevented the deaths of almost 750,000 children in 34 African countries over the past 10 years, according to a report.

16 Sep 2010

K.U.Leuven enters license agreement with Pfizer to commercialize anti-HIV drugs

K.U.Leuven announced today that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise K.U.Leuven's compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS.

16 Sep 2010

Drugs News and Research

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

Forest Pharmaceuticals to pay $300 million as penalty for criminal actions

NMS Labs launches method for K2 drug metabolites detection in urine

Generics drugs in Medicare program saved $33 billion in 2007: CBO

Anonymous Funding promotes drug development for Fragile X syndrome treatment

Researchers to conduct gene analysis for ankylosing spondylitis

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

Wistar Institute scientists publish detailed report on structure, function of Cdc13 domain in protein

Researchers target specific molecule in brain to prevent relapses in cocaine addicts

Advanced Life Sciences participates as exhibitor in 50th ICAAC

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

HHS awards grant to develop patient-centered outcomes research

Renal research consortia receives two grants for translational research from DKF

ESMO honors three eminent cancer specialists for their contribution towards medical research

Daily doses of ginger relieve muscle pain: Research

Milwaukee sees fast rise in costs of benefits; N.J. Gov. outlines cuts to public workers' benefits; Hawaii teachers file suit over health changes

Report: Prevention efforts averted almost 750,000 child Malaria deaths over 10 years

K.U.Leuven enters license agreement with Pfizer to commercialize anti-HIV drugs

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News